Repeat transcatheter aortic valve implantation using a latest generation balloon-expandable device for treatment of failing transcatheter heart valves

Table 1 Clinical baseline data and initial TAVI procedure information

	Patient no. 1	Patient no. 2	Patient no. 3
Age (y)	80	78	71
Gender	female	male	male
BMI (kg/m²)	46.6	21	21.6
Comorbidities	AF, RI, osteoporosis, s/p TKA both sides, AH, NIDDM	AF, 1 VD, prostate cancer, s/p rectum cancer, COPD IV, AH	s/p DES in LAD, 3VD, s/p Mitraclip, AF
logEuroSCORE I (%)	23.92	11.89	32.63
logEuroSCORE II (%)	5.54	2.33	19.14
STS PROM (%)	4.69	3.78	2.744
NYHA	III	III	IV
TTE before index procedure
LVEF (%)	60	50	30
EOA (cm²)	0.9	0.7	0.9
Gradient max/mean (mmHg)	82/41	90/52	30/12
Valve insufficiency	none	none	none
Index procedure
Implanted THV, size (mm)	Edwards Sapien XT, 26	JenaValve, 27	CoreValve, 29
Symptoms after index procedure	syncope, dyspnea	dyspnea	dyspnea
Time to 2^nd procedure (d)	1119	533	814
TTE after index procedure
EOA (cm²)	/	1.9	2.8
Gradient max/mean (mm Hg)	/	27/10	15/9
Valve insufficiency	mild	mild	mild

Y years; BMI body mass index; logEuroSCORE logistic European System for Cardiac Operative Risk Evaluation; STS PROM Society of Thoracic Surgeons Predicted Risk of Mortality; NYHA New York Heart Association; TTE transthoracic echocardiography; LVEF left ventricular ejection fraction; EOA effective orifice area; TAVI transcatheter aortic valve implantation; THV transcatheter heart valve; AF atrial fibrillation; RI renal insufficiency; TKA total knee arthroplasty; AH arterial hypertension; NIDDM non insulin dependent diabetes mellitus; VD vessel disease; s/p status post; COPD chronical obstructive pulmonal disease; PVL paravalvular leakage; SD standard deviation

ISSN: 1749-8090